An Observational Study to Assess Change in Disease Activity and Adverse Events In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AbbVie
Age
15–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants with a diagnosis of Crohn's disease (CD) confirmed by clinical, endoscopic and/or histological indices.
Participants initiating risankizumab at the clinician's discretion as part of their routine clinical care.
Participants prescribed risankizumab in accordance with the approved local label.
Participants able to understand and communicate with the investigator and comply with the requirements of the study.
Participants willing and able to provide authorization to use and disclose personal health information.
Participants willing and able to participate in the collection of patient-reported data via cloud-based mobile application using a smart device (i.e., smartphone).
You may not be if
Females who are pregnant or breast feeding at baseline.
Participants with any contraindication to risankizumab.
Participants previously exposed to risankizumab.
Participants currently participating in an interventional clinical trial.